The new bioinformatics software platform is said to offer comprehensive clinical insights for somatic cancer and constitutional assays.
The company has developed CGW software has for clinical labs to manage their next-generation sequencing processes.
PierianDx CEO Ted Briscoe said: "We have always had a platform that was built by genomicists, for genomicists.
"True to our roots, we designed our new exome release with guidance from the best and brightest minds in the industry."
PierianDx CGW 3.0 provides a highly streamlined workflow inspected by the PierianDx medical advisors.
It includes up-to-the-moment knowledgebase that is constantly incorporating databases across the constitutional space.
The platform uses a complex algorithm, which results in a PDx score highlighting the most relevant and actionable information.
Image: PierianDx CGW 3.0 software provides clinical insights for somatic cancer and constitutional assays. Photo: courtesy of Stuart Miles/ FreeDigitalPhotos.net.
